Giesinger JM, Efficace F, Aaronson N, Calvert M, Kyte D, Cottone F, et al. Past and Current Practice of Patient-Reported Outcome Measurement in Randomized Cancer Clinical Trials: A Systematic Review. Value Health. 2021;24(4):585–91.
Article
PubMed
Google Scholar
Bowen DJ, Shinn EH, Gregrowski S, Kimmick G, Dominici LS, Frank ES, et al. Patient-reported outcomes in the Translational Breast Cancer Research Consortium. Cancer. 2020;126(5):922–30.
Article
PubMed
Google Scholar
Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, et al. Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. JAMA. 2017;318(2):197–8.
Article
PubMed
PubMed Central
Google Scholar
Kennedy-Martin M, Slaap B, Herdman M, van Reenen M, Kennedy-Martin T, Greiner W, et al. Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines. Eur J Health Econ. 2020;21(8):1245–57.
Article
PubMed
PubMed Central
Google Scholar
Longworth L, Yang Y, Young T, Mulhern B, Hernandez Alava M, Mukuria C, et al. Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. Health Technol Assess. 2014;18(9):1–224.
Article
PubMed
PubMed Central
Google Scholar
Brettschneider C, Luhmann D, Raspe H. Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA). GMS Health Technol Assess. 2011;7:Doc01.
PubMed
PubMed Central
Google Scholar
Efficace F, Collins GS, Cottone F, Giesinger JM, Sommer K, Anota A, et al. Patient-Reported Outcomes as Independent Prognostic Factors for Survival in Oncology: Systematic Review and Meta-Analysis. Value Health. 2021;24(2):250–67.
Article
PubMed
Google Scholar
Janssen MF, Bonsel GJ, Luo N. Is EQ-5D-5L Better Than EQ-5D-3L? A Head-to-Head Comparison of Descriptive Systems and Value Sets from Seven Countries. Pharmacoeconomics. 2018;36(6):675–97.
Article
PubMed
PubMed Central
Google Scholar
Wailoo A, Alava MH, Pudney S, Barton G, O'Dwyer J, Gomes M, et al. An International Comparison of EQ-5D-5L and EQ-5D-3L for Use in Cost-Effectiveness Analysis. Value Health. 2021;24(4):568–74.
Article
PubMed
Google Scholar
van Hout B, Mulhern B, Feng Y, Shah K, Devlin N. The EQ-5D-5L Value Set for England: Response to the "Quality Assurance". Value Health. 2020;23(5):649–55.
Article
PubMed
Google Scholar
Sprave T, Zoller D, Stoian R, Ruhle A, Kalckreuth T, Haehl E, et al. App-Controlled Treatment Monitoring and Support for Head and Neck Cancer Patients (APCOT): Protocol for a Prospective Randomized Controlled Trial. JMIR Res Protoc. 2020;9(12):e21693.
Article
PubMed
PubMed Central
Google Scholar
So WK, Chan RJ, Chan DN, Hughes BG, Chair SY, Choi KC, et al. Quality-of-life among head and neck cancer survivors at one year after treatment--a systematic review. Eur J Cancer. 2012;48(15):2391–408.
Article
CAS
PubMed
Google Scholar
Maurer J, Hipp M, Schafer C, Dysphagia KO. Impact on quality of life after radio (chemo) therapy of head and neck cancer. Strahlenther Onkol. 2011;187(11):744–9.
Article
PubMed
Google Scholar
Ackerstaff AH, Rasch CR, Balm AJ, de Boer JP, Wiggenraad R, Rietveld DH, et al. Five-year quality of life results of the randomized clinical phase III (RADPLAT) trial, comparing concomitant intra-arterial versus intravenous chemoradiotherapy in locally advanced head and neck cancer. Head Neck. 2012;34(7):974–80.
Article
PubMed
Google Scholar
Wan Leung S, Lee TF, Chien CY, Chao PJ, Tsai WL, Fang FM. Health-related quality of life in 640 head and neck cancer survivors after radiotherapy using EORTC QLQ-C30 and QLQ-H&N35 questionnaires. BMC Cancer. 2011;11:128.
Article
PubMed
PubMed Central
Google Scholar
Ramaekers BL, Joore MA, Grutters JP, van den Ende P, Jong J, Houben R, et al. The impact of late treatment-toxicity on generic health-related quality of life in head and neck cancer patients after radiotherapy. Oral Oncol. 2011;47(8):768–74.
Article
PubMed
Google Scholar
Truong MT, Zhang Q, Rosenthal DI, List M, Axelrod R, Sherman E, et al. Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522. Int J Radiat Oncol Biol Phys. 2017;97(4):687–99.
Article
CAS
PubMed
Google Scholar
Ludwig K, Graf von der Schulenburg JM, Greiner W. German Value Set for the EQ-5D-5L. Pharmacoeconomics. 2018;36(6):663–74.
Article
PubMed
PubMed Central
Google Scholar
Sprave T, Zamboglou C, Verma V, Nicolay NH, Grosu AL, Lindenmeier J, et al. Characterization of health-related quality of life based on the EQ-5D-5L questionnaire in head-and-neck cancer patients undergoing modern radiotherapy. Expert Rev Pharmacoecon Outcomes Res. 2020;20(6):673–82.
Article
PubMed
Google Scholar
Devlin NJ, Brooks R. EQ-5D and the EuroQol Group: Past, Present and Future. Appl Health Econ Health Policy. 2017;15(2):127–37.
Article
PubMed
PubMed Central
Google Scholar
Sprave T, Nicolay N, Grosu A, Lindenmeier J, Tscheuliln D. The introduction of a permanent survey system to measure the quality of life of ENT patients at the Department of Radiotherapy at the University Hospital of Freiburg: Implementation Report. Gesundheitsökonomie & Qualitätsmanagement. 2020;25(04):195–200.
Google Scholar
Jones DA, Mistry P, Dalby M, Fulton-Lieuw T, Kong AH, Dunn J, et al. Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer: Medical resource use, costs, and quality-adjusted survival from the De-ESCALaTE HPV trial. Eur J Cancer. 2020;124:178–85.
Article
CAS
PubMed
PubMed Central
Google Scholar
Marten O, Greiner W. EQ-5D-5L reference values for the German general elderly population. Health Qual Life Outcomes. 2021;19(1):76.
Article
PubMed
PubMed Central
Google Scholar
Konig HH, Brettschneider C, Luhmann D, Kaduszkiewicz H, Oey A, Wiese B, et al. EQ-5D-3L health status and health state utilities of the oldest-old (85 +) in Germany: results from the AgeCoDe-AgeQualiDe study. Qual Life Res. 2020;29(12):3223–32.
Article
PubMed
Google Scholar
Mangen MJ, Bolkenbaas M, Huijts SM, van Werkhoven CH, Bonten MJ, de Wit GA. Quality of life in community-dwelling Dutch elderly measured by EQ-5D-3L. Health Qual Life Outcomes. 2017;15(1):3.
Article
PubMed
PubMed Central
Google Scholar
Grochtdreis T, Dams J, Konig HH, Konnopka A. Health-related quality of life measured with the EQ-5D-5L: estimation of normative index values based on a representative German population sample and value set. Eur J Health Econ. 2019;20(6):933–44.
Article
PubMed
Google Scholar
You R, Liu J, Yang Z, Pan C, Ma Q, Luo N. Comparing the performance of the EQ-5D-3 L and the EQ-5D-5 L in an elderly Chinese population. Health Qual Life Outcomes. 2020;18(1):97.
Article
PubMed
PubMed Central
Google Scholar
Bhadhuri A, Kind P, Salari P, Jungo KT, Boland B, Byrne S, et al. Measurement properties of EQ-5D-3L and EQ-5D-5L in recording self-reported health status in older patients with substantial multimorbidity and polypharmacy. Health Qual Life Outcomes. 2020;18(1):317.
Article
PubMed
PubMed Central
Google Scholar
Thompson AJ, Turner AJ. A Comparison of the EQ-5D-3L and EQ-5D-5L. PharmacoEconomics. 2020;38(6):575–91.
Article
PubMed
Google Scholar
Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727–36.
Article
CAS
PubMed
PubMed Central
Google Scholar
Buchholz I, Janssen MF, Kohlmann T, Feng YS. A Systematic Review of Studies Comparing the Measurement Properties of the Three-Level and Five-Level Versions of the EQ-5D. Pharmacoeconomics. 2018;36(6):645–61.
Article
PubMed
PubMed Central
Google Scholar
Janssen MF, Birnie E, Haagsma JA, Bonsel GJ. Comparing the standard EQ-5D three-level system with a five-level version. Value Health. 2008;11(2):275–84.
Article
PubMed
Google Scholar
Konnopka A, Koenig HH. The "no problems"-problem: an empirical analysis of ceiling effects on the EQ-5D 5L. Qual Life Res. 2017;26(8):2079–84.
Article
PubMed
Google Scholar
Pickard AS, De Leon MC, Kohlmann T, Cella D, Rosenbloom S. Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients. Med Care. 2007;45(3):259–63.
Article
PubMed
Google Scholar
Leidl R, Reitmeir P. A value set for the EQ-5D based on experienced health states: development and testing for the German population. PharmacoEconomics. 2011;29(6):521–34.
Article
PubMed
Google Scholar
de Almeida JR, Villanueva NL, Moskowitz AJ, Miles BA, Teng MS, Sikora A, et al. Preferences and utilities for health states after treatment for oropharyngeal cancer: transoral robotic surgery versus definitive (chemo)radiotherapy. Head Neck. 2014;36(7):923–33.
Article
PubMed
Google Scholar
Bernert S, Fernandez A, Haro JM, Konig HH, Alonso J, Vilagut G, et al. Comparison of different valuation methods for population health status measured by the EQ-5D in three European countries. Value Health. 2009;12(5):750–8.
Article
PubMed
Google Scholar
Wyrwich KW, Norquist JM, Lenderking WR, Acaster S. Industry Advisory Committee of International Society for Quality of Life R. Methods for interpreting change over time in patient-reported outcome measures. Qual Life Res. 2013;22(3):475–83.
Article
CAS
PubMed
Google Scholar
Health USDo, Human Services FDACfDE, Research, Health USDo, Human Services FDACfBE, Research, et al. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes. 2006;4:79.
Article
Google Scholar
Revicki DA, Cella D, Hays RD, Sloan JA, Lenderking WR, Aaronson NK. Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes. 2006;4:70.
Article
PubMed
PubMed Central
Google Scholar